Navigation Links
WuXi PharmaTech Schedules Fourth-Quarter 2010 Earnings Release
Date:3/1/2011

SHANGHAI, March 1, 2011 / PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2010 after the New York Stock Exchange closes on Tuesday, March 8, 2011 (which will be Wednesday morning, March 9, 2011 Shanghai time). The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Wednesday, March 9, 2011, to discuss the fourth-quarter 2010 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004China (Landline):

800-819-0121China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381Conference ID:

47994432A telephone replay will be available two hours after the call's completion at:

United States:

1-866-214-5335China North:

10-800-714-0386China South:

10-800-140-0386Hong Kong:

800-901-596United Kingdom:

0-800-731-7846International:

+61-2-8235-5000Conference ID:

47994432A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please contact:Ronald AldridgeDirector of Investor RelationsWuXi PharmaTech (Cayman) Inc.Tel:   +1-201-585-2048Email: Ron_Aldridge@wuxiapptec.comWeb: http://www.wuxiapptec.com
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- According to a new market research report "Gynecology ... (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End User (Hospital, Clinic, ... the global market is expected to reach USD 2.44 Billion by ... 7.1% during the forecast period. Continue ... ...
(Date:2/22/2017)... 22, 2017 Arthroscopy Devices Market Report, published by Allied Market ... is projected to reach $5,334 million by 2022, growing at a CAGR of 6.2% ... market in 2015. Continue Reading ... ...      ...
(Date:2/22/2017)... Research and Markets has announced the ... 2016" report to their offering. ... Dermatological conditions are one ... one-third of the US population suffers from at least one ... the dermatology market has remained saturated with established and generic ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... a contract to Quality Insights to help small practices in Delaware, New Jersey, ... Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). ...
(Date:2/22/2017)... Cranbury, NJ (PRWEB) , ... February 22, 2017 ... ... full-service healthcare communications company, launched a new media platform connecting healthcare technology professionals ... which will be followed by a quarterly publication starting on March 1, announced ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. ... dogs, according to the Association for Pet Obesity Prevention (APOP). During the ninth annual ... issues such as the benefits of corn and grains, value of raw and organic ...
(Date:2/22/2017)... Dallas, TX (PRWEB) , ... February 22, 2017 ... ... of security threats. Yet with so many different solutions on the market, it ... through their choices, Texas Premier Locksmith offers a complimentary security consultation. ...
Breaking Medicine News(10 mins):